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Active site mutantFarnesyl pyrophosphate synthase (FPPS) is the major molecular target of nitrogen-containing bisphosphonates
(N-BPs), used clinically as bone resorption inhibitors.We investigated the role of threonine 201 (Thr201) and ty-
rosine 204 (Tyr204) residues in substrate binding, catalysis and inhibition by N-BPs, employing kinetic and crys-
tallographic studies of mutated FPPS proteins.
Mutants of Thr201 illustrated the importance of themethyl group in aiding the formation of the Isopentenyl py-
rophosphate (IPP) binding site, while Tyr204mutations revealed the unknown role of this residue in both catal-
ysis and IPP binding. The interaction between Thr201 and the side chain nitrogen of N-BP was shown to be
important for tight binding inhibition by zoledronate (ZOL) and risedronate (RIS), although RIS was also still ca-
pable of interactingwith themain-chain carbonyl of Lys200. The interaction of RISwith the phenyl ring of Tyr204
proved essential for the maintenance of the isomerized enzyme-inhibitor complex. Studies with
conformationally restricted analogues of RIS reafﬁrmed the importance of Thr201 in the formation of hydrogen
bonds with N-BPs.
In conclusionwe have identiﬁed new features of FPPS inhibition byN-BPs and revealed unknown roles of the ac-
tive site residues in catalysis and substrate binding.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).; FPP, farnesyl pyrophosphate;
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Farnesyl pyrophosphate synthase (FPPS) is a key branch point en-
zyme in themevalonate pathway, the exclusive route of isoprenoid pro-
duction in animals, involved in cholesterol biosynthesis and synthesis of
intermediates important for intracellular signalling and growth control
[1]. Inhibition of FPPS causes a reduction in farnesyl pyrophosphate
(FPP) and geranylgeranylpyrophosphate (GGPP) levels leading to im-
paired prenylation and defective intracellular localization of GTPase sig-
nalling proteins such as Ras, Rho and Rac [2,3]. These proteins are
essential for osteoclast cell processes such as bone resorption, cell
movement, cytoskeletal rearrangement and apoptosis [4,5]. FPPS has
been conﬁrmed as the primary molecular target of the nitrogen-
containing bisphosphonates (N-BPs) that are potent inhibitors of osteo-
clastic activity [6]. Several members of this class are important clinicallythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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such as Paget's disease [7], multiple myeloma [8], bone metastases [9]
and osteoporosis [10,11].
FPPS is a homodimeric enzyme, made up of two 42 kDa monomers,
that initially catalyse a head-to-tail condensation of the 5-carbon allylic
substrate dimethylallyl pyrophosphate (DMAPP) with isopentenyl
pyrophosphate (IPP) to yield the C10 geranylpyrophosphate (GPP). Sub-
sequently, a second head-to-tail condensation of GPP and IPP within
this enzyme yields the C15 farnesyl pyrophosphate (FPP). The reac-
tion is thought to proceed by a highly ordered three step
ionization-condensation-elimination mechanism, via the formation
of a carbocation intermediate, which is stabilized by the presence
of the OH group of Thr201, the main-chain carbonyl oxygen of
Lys200 and the side chain oxygen of glutamine 240 [12–14]. The ion-
ization of DMAPP is facilitated by the enzyme-bound tri-nuclear
Mg2+ cluster where all three Mg2+ ions form salt-bridges with the
un-esteriﬁed oxygens of the pyrophosphate, enhancing the juxtapo-
sition of the hydrophobic C5 isoprenoid tail of the IPP into the correct
conformation for subsequent catalysis [12,15]. The carbocation
formed condenses with the nucleophilic C3–C5 double bond of IPP.
Finally, elimination of the isoprenoid reaction product, GPP, is
achieved by de-protonation of the condensed intermediate by the
free pyrophosphate oxygen [12].
The structures of human FPPS co-crystallised with several clinically
utilised N-BPs demonstrated that N-BPs occupy the “allylic substrate
binding pocket” (DMAPP/GPP) of FPPS, in agreementwith the proposed
kinetic model [16,17]. Coordination of the phosphonate groups of N-BP
is facilitated via interactions of Mg2+ ions with the same aspartate-rich
motifs of FPPS that bind the pyrophosphate moieties of the allylic sub-
strate [16]. In the case of two of the most potent inhibitors of FPPS,
risedronate (RIS) and zoledronate (ZOL), the N-BP binding is strength-
ened by hydrogen bond interactions of the protonated nitrogen atom
within the heterocyclic ring of the side chain of the N-BP with theTable 1
BPs used in the study.conserved main-chain carbonyl oxygen of Lys200 and the hydroxyl
group of the Thr201 side chain, mimicking the stabilization of a
carbocation intermediate [12,16–18]. In the case of pamidronate
(PAM), the position of the hydroxyl of the Tyr204 is found close to the
amino-group in the alkyl side chain of PAM (3Å) and, favours formation
of a hydrogen bond thus accounting for the intermediate to weak en-
zyme inhibitory effect of PAM [17]. The N-BP:FPPS interactions are com-
plex in nature due to N-BPs having two different modes of inhibition: a
rapid and reversible competitive inhibition with regard to the allylic
substrate DMAPP/GPP, reﬂecting the inhibition constant Ki, and an un-
competitive or mixed-type inhibition in relation to IPP [16,19]. The lat-
ter is a time-dependent inhibition, arising due to an enzyme
isomerization occurring in two stages: i) N-BP binds to the allylic site
and forms the IPP binding site and ii) IPP binds to the FPPS:N-BP com-
plex and closes the active site using amino acid residues found in the
C-terminus of FPPS (Lys350, Arg351, Arg352, Lys353) [16,17]. This com-
plex inhibition mechanism is expressed as a ﬁnal isomerized inhibition
constant Ki*. The tendency of the enzyme to remain in the isomerized
state is given by the isomerization constant, Kisom = (Ki− Ki*) / Ki*.
The biological effects of the bisphosphonates are still being exten-
sively studied and many new applications are emerging, including im-
provements to current therapies [20,21]. There is also interest in
mevalonate pathwaymodulation as a potential target for the treatment
of diseases caused by protozoan parasites, such as toxoplasmosis [22],
leishmaniasis [23,24], Chagas disease [25,26] and malaria [27,28]. An
understanding of the molecular interaction of pivotal FPPS amino-acid
residues with the side chain of selected BPs (Table 1) may enable the
synthesis of additional N-BP analogues that will selectively target the
FPPS enzymes in humans and other species. For the applications focused
more on non-skeletal tissue targets, developments in the design and
measurements of lower bone afﬁnity bisphosphonates have evolved
that may advance the utility of the class, both with regards to lower
skeletal uptake and enhanced activity [6].
Table 2
Kinetic parameters calculated for FPPS wtFPPS and mutantsa.
WT T201S T201A Y204F Y204A
KmGPP(μM) 2.1 ± 0.2 1.2 ± 0.1 1.5 ± 0.2 1.8 ± 0.6 2.1 ± 0.4
KmIPP(μM) 1.8 ± 0.3 10.6 ± 1.1 18 ± 2 34 ± 5 44 ± 5
kcat(s−1) 0.42 0.24 0.39 0.085 0.052
kcat/KmGPP(μM−1 · s−1) 0.20 0.20 0.26 0.047 0.025
kcat/KmIPP(μM−1 · s−1) 0.23 0.023 0.022 0.0025 0.0012
a Results are expressed as means ± SEM, n ≥ 6, R2 ≥ 0.95.
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and Tyr204 as two pivotal active site residues contributing to the inhib-
itory action of the more potent N-BPs we have sought to deﬁne their
roles in greater detail. This has been enabled by the generation of the
threonine-to-serine (T201S) and tyrosine-to-phenylalanine (Y204F)
mutants, which we hypothesised would not disrupt the proposed
Thr201:N-BP hydrogen bond and hydrophobic interactions respectively
whereas a Thr201 to alanine (T201A) and Tyr204 to alanine (Y204A)
mutant should abolish such interactions.
2. Methods
Oligonucleotides were purchased from Euroﬁns MWG. Modiﬁed
standard Expression LIC vectors were all based on pET-28a (Novagen,
Madison, USA) and were provided by Structural Genomics Consortium,
Oxford, UK. Unlabelled geranyl pyrophosphate (GPP) and isopentenyl
pyrophosphate (IPP) were purchased from Isoprenoids LC (Tampa FI,
USA). Isopentenyl Pyrophosphate (1-14C) triammonium salt was pur-
chased from American Radiochem Corp UK Ltd (Cardiff, UK). All BPs
were obtained from Procter and Gamble Pharmaceuticals (Cincinnati,
USA), except PAM and ALN which were from Sigma.
2.1. Manufacture of mutants
Generation of FPPS mutants was carried out with QuickChange Site-
directed mutagenesis kits from Agilent Technologies used according to
manufacturer's instructions. Mutations were conﬁrmed by DNA se-
quencing analysis (LARK Technologies, Takeley, UK) and by ESI-TOF
mass spectrometry (Agilent).
2.2. Expression and puriﬁcation of recombinant human FPPS
FPPS was expressed as described previously [16].
2.3. FPPS synthase assay
FPPS activity was measured as described previously [16].
2.4. Kinetic models and calculations of constants
Data were ﬁtted to the appropriate kinetic models by nonlinear
regression analysis using Graphpad Prism®. Determination of tight-
binding ligand characteristics were analysed based on the equation
developed by Morrison [29].
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Initial inhibition constant (Ki), overall inhibition constant (Ki*) and
isomerisation constant (Kisom) values were calculated as previously de-
scribed [19].
2.5. Crystallization and data collection of human FPPS with N-BPs
Tobacco etch virus protease-cleaved FPPSwas concentrated up to 15
mg/ml. N-BPswere prepared as a 20mMstock solution in 100mMTris–
HCl pH 7.7 andwere added to a ﬁnal concentration of 2mM. MgCl2 was
prepared as a 100 mM aqueous stock solution and added to a ﬁnal con-
centration of 4mM. Crystals were grown by vapour diffusion at 20 °C in
300 nl sitting drops by mixing 200 nl of protein solution with 100 nl of
precipitant. For the 4Q23 structure the precipitant was 2 M (NH4)2SO4,
0.1M Acetate, pH 4.6 for all other structures the precipitant consisted of0.2 M NH4Cl, 20% (w/v) PEG 6000, 10% ethylene glycol, pH 7.5. A single
crystal was transferred to cryoprotectant solution composed of 20% (v/v)
ethylene glycol and 80% well solution and ﬂash cooled in liquid
nitrogen.
2.6. Data processing and reﬁnement
Indexing and integration of collected data was performed using
MOSFLM [30] and symmetry-related reﬂections were scaled by SCALA
[31] and converted into amplitudes by TRUNCATE. Initial phases for
the FPPS:N-BP complexes were calculated by molecular replacement
implemented in PHASER [32] using the wtFPPS FPPS in complex with
ZOL (PDB code: 1ZW5) as a starting model. Iterative rounds of model
building in COOT [33] and reﬁnement using REFMAC5 [34] resulted in
the ﬁnal models. All reﬁned structures have been deposited into the
Protein Data Bank (Table 6).
3. Statistical analysis
Ki, Ki* and Kisom were analysed for signiﬁcance using oneway Anova
with a Tukey's post hoc test and also by Students T-Test. Inhibition ki-
netic curves were further differentiated by comparing best ﬁt values
for IC50 to selected data sets using an F-test. All statistical analysis was
performed with Graphpad Prism®
4. Results
4.1. Kinetic data for T201S, T201A, Y204F, Y204A
Determination of kinetic parameters for all mutants (Table 2) re-
vealed a Km for the allylic GPP substrate comparable to that of the
wtFPPS (Tukey post-hoc test, p N 0.5), with the exception of T201S
FPPS where the KmGPP was slightly lower (p b 0.01). The KmIPP was signiﬁ-
cantly increased in all mutants with Y204A showing the greatest (24-
fold) increase. Consequently, the catalytic efﬁciency (kcat/Km) for the
Thr201 mutants was unaffected with respect to GPP but decreased for
the other mutants, whereas all the other mutants showed reduced cat-
alytic efﬁciency with regard to IPP.
4.2. The pH activity proﬁle of Tyr204 FPPS mutants
The side chain of Tyr204 has a hydroxylmoietywhich could conceiv-
ably act as a proton donor during catalysis. This abilitywill varywith the
pH of the surrounding solvent. To investigate this possible role the cat-
alytic activity forwtFPPS and Tyr204mutated FPPS constructs was eval-
uated at nine different pH conditions (Fig. 1). The pH proﬁle obtained
for wtFPPS is a typical bell shape curve, where catalytic activity is opti-
mal at pH values ranging from 6 to 8 and is reduced at either high or
low pH. This pattern indicates the presence of two ionizing groups tak-
ing part in catalysis, expressed by two different pKa values calculated as
5.3 and 9.3. This is in striking contrast to both of the Tyr204 mutants
which display their highest catalytic turnover in an acidic environment.
The reduction of catalytic activity in the Tyr204 mutants supports the
suppression of an ionization mechanism involving the hydroxyl of
Tyr204. The elevated enzymatic activity at low pH appears to
Table 3
Estimation of initial inhibition (Ki), isomerised inhibition (Ki*) and Kisom of WT, Thr201
and Tyr204 FPPS mutants derived from inhibition assays with N-BPsa.
Compound Construct Ki (nM) Ki* (nM) Kisom
RIS WT
T201S
T201A
Y204F
Y204A
56.6 ± 3.1
38.7 ± 3.0
61.6 ± 10.8
58.3 ± 4.5
17.7 ± 1.3
0.8 ± 0.06
0.05 ± 0.01
0.16 ± 0.03
2.3 ± 0.4
3.2 ± 0.8
69.7
773
384
24.3
4.5
ZOL WT
T201S
T201A
Y204F
Y204A
62.9 ± 5.1
82.1 ± 4.0
72.7 ± 5.0
54.2 ± 4.4
29.8 ± 3.1
0.06 ± 0.03
0.23 ± 0.1
2.2 ± 0.3
ND
ND
1047
355
32.0
ND
ND
PAM WT
T201S
T201A
Y204F
Y204A
181.5 ± 6
262.8 ± 27.6
132.0 ± 14.9
199.9 ± 10.4
195.6 ± 9.8
51.9 ± 3.3
43.7 ± 5.7
45.0 ± 5.0
21.7 ± 1.8
73.6 ± 7.7
2.5
5.0
1.9
8.2
1.7
IBN WT
T201S
T201A
Y204F
Y204A
207.7 ± 13.4
48.6 ± 5.3
31.8 ± 3.6
233.1 ± 10.5
142.2 ± 6.0
4.6 ± 0.4
8.1 ± 0.8
5.5 ± 0.6
2.9 ± 0.6
4.3 ± 0.8
44.1
5.0
4.8
79.3
32.1
ALN WT
T201S
T201A
Y204F
Y204A
388.3 ± 31.3
118.1 ± 4.8
191.9 ± 20.2
431.2 ± 37.3
253.9 ± 14.4
56.5 ± 4.9
81.9 ± 7.5
86.5 ± 7.6
7.3 ± 1.0
26.9 ± 2.5
5.9
0.4
1.2
58.1
8.4
ND: not determined. Results are expressed as means ± SEM, R2 N 0.95 and n ≥ 6.
a Ki and Ki*and Kisom calculated as described.
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droxyl moiety.
4.3. Examination of the IPP binding site in the FPPS mutants
To investigate the reduction in IPP binding afﬁnity for the FPPS mu-
tants, we compared structures of wtFPPS and mutant FPPS. In all the
crystallographic models of FPPS:BP:IPP ternary complexes, IPP is held
in place by hydrogen-bonding and salt-bridge interactions with Gln96
and Arg60. In addition, Gln96 is held in place by a hydrogen bond
with Tyr204 and Arg60 is positioned by a hydrogen bond with Ser205
(Fig. 2A). A comparison of apo, binary and ternary wtFPPS structures
shows that both Gln96 and Arg60 are in optimal positions for IPP bind-
ing whether ligands are present or not (Fig. 2B). Disruption of the
Gln96-Tyr204 hydrogen bond, as occurs in the Tyr204 mutants, allows
Gln96 to adopt a more extended conformation, observed in our Y204A
mutant binary complexes (4KQ5, 4KPJ). This extendedGln96 conforma-
tion also pushes Arg60 away from its optimal position for IPP binding
(Fig. 2C). As a result of these conformational changes both Gln96 and
Arg60 are forced to readjust position when IPP binds to the mutant en-
zymes. Despite the presence of the Tyr204 hydroxyl this extended
Gln96 conformation was also observed in Thr201 mutants (2QIS,
4KFA) (Fig. 2D) and is possibly due to more ﬂexibility in the active site
in the Thr201 mutants compared to wtFPPS. The hydroxyl moiety's ofTable 4
Estimation of initial inhibition (Ki), isomerised inhibition (Ki*) and Kisom of wtFPPS and T201A
Analogues of RIS Enzyme Ki (nM
NE58018 WT
T201A
58.9
50.9
NE58022 WT
T201A
365.0
302.1
NE58025, 1R6S WT
T201A
710.9
192.0
NE58025, 1S6R WT
T201A
2762
1541
Results are expressed as means ± SEM, R2 N 0.95 and n ≥ 4.
a Ki and Ki* and Kisom calculated as described in experimental session.both residues play a role in formation of the IPP binding site in the
wtFPPS. Consequently, IPP must induce changes in the mutant enzyme
architecture for productive IPP binding to occur, while the active site is
already favourable for IPP binding in wtFPPS. The need for the Gln96
and Arg60 side chains to move into position for productive IPP binding
likely explains the increase in KmIPP observed for the mutant enzymes.
4.4. The role of the methyl group of Thr201 in RIS binding
The conservative T201Smutation, which was expected to have little
effect onN-BP inhibition, signiﬁcantly increased both the initial compet-
itive inhibition and also the ﬁnal isomerized inhibition with a reduction
in Ki and Ki*(p b 0.01) of RIS (Table 3). The crystal structure of T201S
with RIS (2QIS) revealed no alteration in the positioning of RIS in the al-
lylic binding pocket and conﬁrmed the maintenance of the hydrogen
bond network between the carbonyl of Lys200 and hydroxyl of Ser201
with the nitrogen moiety of RIS (Fig. 3A). Similarly, the position of
Mg2+ ions and the aspartate motifs (Asp103, Asp107 and Asp243)
remained unaffected by themutation. The RIS position did not shift sig-
niﬁcantly in the binding pocket and it is unclearwhich interactions con-
tribute to the observed increased inhibition. Interestingly, the T201A
mutation, which was predicted to have reduced inhibition by RIS, had
no effect on Ki but showed a small increase in overall inhibition (i.e. a
small decrease in Ki*). Disruption of the Thr201:RIS hydrogen bond in
the T201A FPPS did not affect the orientation of the heterocyclic ring
of RIS or the relative positions of key amino acids in the allylic binding
pocket.
4.5. Kinetic studies of T201A with RIS analogues
The role of Thr201:N-BP hydrogen bond in enzyme inhibition was
further investigated via kinetic studies with RIS analogues NE58018,
NE58022, 8, 9 (Table 1). The lack of the nitrogen atom in NE58022 ren-
ders the analogue incapable of forming the hydrogen bond network
with Lys200 and Thr201 and, as expected, the T201A mutation had no
effect on the inhibition proﬁle of NE58022 (Table 4). Because of the al-
tered position of the nitrogen in NE58018, this analogue is less capable
of forming a hydrogen bond between the heterocyclic ring and the hy-
droxyl moiety of Thr201 and thus becomes a weaker inhibitor of FPPS
compared to RIS [19]. The inhibition of T201A FPPS byNE58018was de-
creased by approximately 3-fold in the T201A mutant (Table 4) reduc-
ing the Kisom.
In order to further investigate the importance of the interaction of
the bisphosphonate nitrogen with Thr201 a conformationally restricted
pair of analogues of RIS, NE58025 1R6S and NE58025 1S6R [6] were
used for inhibition studies and crystallography. The double ring struc-
ture of the analogues means that compound NE58025 1R6S can only
bind the enzyme with the side chain nitrogen in a similar position to
that of RIS and should be able to form the hydrogen bond with
Thr201. Compound NE58025 1S6R however can only bind FPPS with
the side chain nitrogen away from the Thr201 with the prediction this
will be the weaker inhibitor. In accordance with our predictions,FPPS mutants derived from inhibition assays with analogues of RISa.
) Ki* (nM) Kisom
± 3.6
± 5.0
0.7 ± 0.1
2.1 ± 0.2
83.1
23.2
± 15.9
± 17.6
301.0 ± 17.6
302.4 ± 27.9
0.2
0.0
± 35.8
± 11.0
1.7 ± 0.2
13.3 ± 4.0
417
13.4
± 167
± 237
50.7 ± 7.7
53.5 ± 11.5
53.4
27.8
Table 5
IC50 values of mutant enzymes for ﬁnal inhibition of ZOL, compared to the wtFPPS inhibi-
tion data.
Enzyme [Enzyme]
nM
Theoretical max IC50 (nM)
ZOL
Experimental IC50ZOL
(nM)
Y204F 134 67 34 ± 2.2
Y204A 292 146 92.9 ± 5.3
WT 8 4 3.8 ± 0.2
Fig. 1. Optimal catalytic activity of wtFPPS and Tyr204 FPPS mutants is observed in differ-
ent pH environment. The catalytic proﬁle of wtFPPS is a bell shape curve with optimal ca-
talysis observed at pH values between 6 to 8. Optimal catalysis in Y204F and Y204A FPPS
mutants is observed in anacidic environment. Graph representsmeansobtained from four
individual experiments.
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though NE58025 1R6S becomes a stronger competitive inhibitor in
the initial stage of inhibition with T201A, the overall inhibition was re-
duced in the T201A mutant with an 8-fold increase in Ki* and approxi-
mately 30-fold reduction in the Kisom relative to wtFPPS. Compound
NE58025 1S6R was a much weaker inhibitor and overall inhibition
was virtually unaffected by the T201A replacement (Table 4).
4.6. The inhibition of Tyr204 mutants by RIS
In the Tyr204 FPPS mutants the competitive inhibition by RIS was
virtually unaffected by the Y204F substitution yielding a Ki comparable
to that ofWT, but Ki was signiﬁcantly reduced in the Y204Amutant (p b
0.001) (Table 3). However, the Ki* is signiﬁcantly increased in both
Y204A FPPS (p b 0.05) and Y204F FPPS. Alterations in the IPP binding
site described above did not affect the position of RIS in the binding
pocket in either mutant (Fig. 4A). We postulate that changes in electro-
static interactions between RIS and the mutated residue contributed to
the decreasedﬁnal inhibition aswell as an increase in the reversibility of
the enzyme isomerisation, as shown by the reduced isomerisation con-
stant Kisom. These results conﬁrm that the presence of the aromatic ring
and the hydroxyl moiety of Tyr204 do not play a role in the initial bind-
ing of RIS to the allylic site of FPPS, but are essential for isomerisation of
the enzyme to its ﬁnal closed conformation.
4.7. Inhibition of Thr201 and Tyr204 mutants by ZOL
ZOL is shown to form a hydrogen bond with the hydroxyl of Thr201
via the nitrogen in the side chain (1ZW5, 2F8Z) and it was predicted
that the replacement of this residue with an Ala would disrupt this
bonding and reduce the overall inhibition of the enzyme. The replace-
ment of Thr201 by Ala resulted in a signiﬁcant increase in Ki* and reduc-
tion in Kisom (p b 0.001) by ZOL but does not have any impact on the
initial Ki value (Table 3). The replacement of Thr201 by a Ser residue
should rescue the loss of inhibition, and indeed this was the case
(Table 3). The lack of the Thr201: ZOL hydrogen bond in the T201A
FPPS structure (4KFA) does not greatly alter the position of the imidaz-
ole ring in the allylic binding pocket, as it is still properly oriented by the
Lys200:ZOL hydrogen bond (Fig. 3B).
The Y204F FPPSmutant exhibited no alteration in Ki for ZOLwith re-
spect to thewtFPPS (Table 3). However the assessment of Ki* for ZOL in
both the Y204F and Y204A mutants was problematic as the general as-
sumption of a 1:1 enzyme:inhibitor binding ratio as used in all the other
Ki* determinations did not appear valid in this case. The estimation of
inhibitor concentration required for 50% inhibition (IC50) corresponded
to a value lower than half of the enzyme concentration, making the de-
termination of Ki* and Kisom impossible. The IC50 was the only available
way of determining the strength of ZOL inhibition (Table 5). The sameTable 6
Summary of crystallographic models.
Enzyme complex T210S-RIS T201A-RIS T201A-ZOL Y204F-RIS-
PDB accession code 2QIS 4Q23 4KFA 4KPD
Resolution (Å) 1.80 1.98 1.98 1.96
Rwork/Rfree (%) 17.8/20.6 19.2/22.3 18.1/20.1 19.4/22.6Y204F and Y204A preparations did not exhibit this behaviour with
other inhibitors and identical solutions of ZOL showed normal tight
binding with wtFPPS enzyme (Table 3). One possible explanation is
that one molecule of ZOL is capable of inhibiting both molecules of
FPPS in the enzyme dimer, however we have no corroborating evidence
for this theory. The crystal structure of Y204A FPPS in complexwith ZOL
showed no alterations in the electrostatic interactions and position of
key residues in the formation of the allylic binding pocket (Fig. 4B).
4.8. Interaction of amino-alkyl BPs with the Thr201 and Tyr204 mutants
In enzyme inhibition experiments, all of themutants examinedwith
the exception of Y204F showed that the ﬁnal inhibition of FPPS by PAM,
ALNand IBNwasnarrowly affected by changes to Thr201 or Tyr204. The
competitive inhibition of IBN and ALN was increased in both the T201S
and T201A enzymes (Table 3). The implication is that the active site of
these mutants allows better initial binding of ALN and IBN. However,
overall inhibition and Kisom are decreased suggesting that binding in
the isomerized state is less tight. The results for PAM are mixed with it
being a slightly better competitive inhibitor for T201A and somewhat
weaker competitive inhibitor for T201S. The structure of wtFPPS with
PAM (2 F89) does not offer any insights as to why this would be so
since in that structure the PAM nitrogen is within hydrogen-bonding
distance of the Tyr204 hydroxyl (3.0 Å) and does not interact directly
with Thr201.
Interestingly, the Ki values obtained for both Tyr204 mutants with
PAM were similar to the wtFPPS, indicating that, even after disruption
of any putative hydrogen bond between PAM and the Tyr residue, the
BP is still capable of competing with GPP. Finally, the overall inhibitionIPP Y204A-PAM Y204A-ZOL Y204A-RIS-IPP Y204A-ALN-IPP
4KPJ 4KQ5 4KQS 4KQU
1.95 1.97 1.97 2.07
17.2/21.5 17.0/20.4 17.0/20.4 17.6/20.1
Fig. 2. Interactions in the IPP binding site. Hydrogen-bonding interactions for Gln96 and Arg60 are shown for theWT+ZOL+ IPP structure (grey carbons, 1ZW5) as dashed yellowdotted
lines. A)Gln96 andArg60 electrostatic interactionswith IPP, Tyr204 and Ser205 as seen inWT+ZOL+ IPP. Distances for H-bonds are given inÅ. B)Overlay of apowtFPPS (yellow, 2F7M),
WT+RIS (pink, 1YV5) andWT+ZOL+ IPP FPPS crystal structures showing conserved orientation of Gln96 and Arg60. C) In FPPS tyrosinemutants Y204A+ZOL (bluegreen, 4KQ5) and
Y204A+PAM(light green, 4KPJ)Gln96 adopts an extended conformation that pushes Arg60 away from its optimal IPP bindingposition. D) In Thr201 FPPSmutants, T201A+ZOL (purple,
4KFA) and T201S + RIS (light blue, 2QIS), Gln96 and Arg60 adopt similar conformations as described for Tyr204 mutants.
Fig. 3. Structures of Thr201mutantswith N-BPs. A) Overlay ofWT+RIS (grey, 1YV5), T201S+RIS (light blue, 2QIS) and T201A+RIS (plum, 4Q23). H-bonds are shown as yellow dashed
lines and distances (Å) are given for RIS in the T201S structure. B) T201A+ ZOL (purple, 4KFA) superimposed ontoWT+ ZOL+ IPP (grey, 1ZW5). H-bond distances (Å) for the ZOL ni-
trogen are shown in yellow for wtFPPS and grey for T201A.
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Fig. 4. Structures of Tyr204mutantswith bound inhibitor. A) Overlay ofWT+RIS (grey, 1YV5), Y204F+RIS+ IPP (darkgreen, 4KPD) and Y204A+RIS+ IPP (lightgreen, 4KQS). H-bond
distances (Å) for the RIS nitrogen are given forwtFPPS andRIS position is unaffected by the Y204mutation. B) Y204A+ZOL (bluegreen, 4KQ5) superimposed ontoWT+ZOL+ IPP (grey,
1ZW5). H-bond distances (Å) for the ZOL nitrogen are given for Y204A. C) Superimposition of WT+ ZOL+ IPP (grey, 1ZW5), Y204F+ RIS+ IPP (darkgreen, 4KPD), Y204A+ RIS+ IPP
(lightgreen, 4KQS) and Y204A+ALN+ IPP (yellow, 4KQU). In wtFPPS the IPP is sterically constrained between Asp243 and the Tyr204 hydroxyl (distances (Å) shown as dashed yellow
lines). In Y204A and Y204F, lack of the hydroxyl allows the IPP C4 to shift ~0.9 Å into amore hydrophobic pocket. Distance from the IPP C4 in Y204F+ RIS+ IPP to the positionwhere the
Tyr hydroxyl would be is shown in grey.
484 M.K. Tsoumpra et al. / Bone 81 (2015) 478–486of Y204F FPPS was signiﬁcantly increased by ALN and less so by PAM
and IBN (p b 0.01). One possible explanation is that the IPP forms a
tighter complex, with the amino-alkyl BPs in Y204F. In the wtFPPS ter-
nary structure, the IPP tail is sterically constrained between Asp243
(3.4 Å) and the Tyr204 hydroxyl (3.6 Å). Without the hydroxyl present,
the IPP C4 can shift 0.9 Å toward Phe204 and into a more hydrophobic
environment, as seen in Y204F-RIS-IPP (Fig. 4C). For PAM, this hydro-
phobic interaction is lost in the Y204Amutant and is reﬂected in the re-
turn of Ki* to slightly more than wtFPPS (Table 3).
5. Dscussion
The availability of crystal structures of FPPS in complex with
bisphosphonates identiﬁed several active site residues that could play
a role in N-BP binding and also in catalysis. Here we use mutants of
human FPPS complexed with BPs to elucidate the involvement of
Tyr204 and the aliphatic portion of the Thr201 side chain in FPPS sub-
strate binding, in the catalytic mechanism, and in interactions with N-
BPs that can inﬂuence the strength of drug binding.
Given the high degree of conservation of Thr201 and Tyr204 among
different species, along with computer modelling and structure activity
relationship studies of BP inhibitors [16,17,35], it was postulated that
these residues play a pivotal role in allylic substrate binding. Surprising-
ly, no major alteration in KmGPP was observed in all the FPPS mutants ex-
amined here even though in the Escherichia coli FPPS calculations of the
stabilization effect of Thr201 on the carbocation species (1.5 Kcal/mol)
suggest a more substantial role of the Thr201 residue in catalysis than
the one reported here [35]. Compensation by the other active site resi-
dues predicted to stabilize the carbocation intermediate, such as
Gln240 and the carbonyl of Lys200, [12,17] might account for this lack
of effect.
Unexpectedly, there was an increased KmIPP for all the mutants sug-
gesting a role of the methyl group of Thr201 in the formation of the
IPP binding site; however it was the Tyr204 mutants that showed a
greater reduction in afﬁnity for IPP. This reduced binding of IPP in
both Tyr204 mutants suggests involvement of this residue in the
isomerisation event responsible for the formation of the IPP binding
site, the orientation of the IPP substrate, or in the stabilization of the
carbocation. Our crystal structures of Tyr204 FPPS mutants provide ev-
idence that the Tyr204 hydroxyl forms a hydrogen bond network that
correctly orients the IPP-binding residues Gln96 and Arg60 making
Tyr204 an essential residue in the second substrate binding event/cata-
lytic process.In our early experiments we detected the abolition of the acidic pKa
value in Tyr204mutants, a result which indicates the disruption of a pos-
sible ionizationmechanism [36]. Considering that the pKa value of the ty-
rosine group is approximately 10, the reduced pKa value of the wtFPPS
enzyme might correspond to an interaction of the Tyr204 residue with
an adjacent basic residue such as Arg60 or Arg112. These results suggest
a possible role of the hydroxyl group of Tyr204 as a proton donor where
its removal alters the pH activity proﬁle of the enzyme. If the ionization
step in FPPS catalysis progresses via removal of a negative charge from
the allylic pyrophosphate [13], formation of a tyrosinate ion, derived
from the interaction of the OH group of Tyr with the basic Arg residues
(such asArg112/Arg60) in the vicinity could accelerate the reaction.How-
ever the higher activity of the Tyr204 mutants observed at low pH is in-
consistent with the proposal that such a tyrosinate ion acts to force IPP
into a catalytically competent position, but rather backs up the theory
that the stabilization of the PPi leaving group facilitated by the tri-
nuclear Mg cluster helps drive the reaction [12]. Chemical rescue experi-
ments of the mutated tyrosine by addition of lowmolecular weight phe-
nols failed to substitute for the loss of the pKa of a titratable group or to
restore the catalytic activity (data not shown). In addition, it is not always
possible to attribute a pKa value to a single group, as an ionization state
observed might be the outcome of multiple ionizing groups taking part
in catalysis [37].
The position of the nitrogen relative to the phosphonate groups in the
bisphosphonate is critical for inhibitor potency as we have shown previ-
ously [19]. In the case of RIS itwas surprising that inhibitionwas not really
affected by the T201A mutation as placement of the nitrogen away from
the optimal position on the ring leads to a drop in potency, however it
is possible that interaction with the Lys200 carbonyl makes up for the
lack of interaction with the Thr201 hydroxyl moiety. In this scenario the
nitrogen of RIS needs to be protonated and it is uncertain whether RIS
in the active site is protonated [38] at the usual pH at which the crystals
are grown (pH 7.5). The T201A mutant structure 4Q23 was crystallised
at pH 4.6 and hence should be protonated in this structure. ZOL however
is mainly protonated at pH 7.5 and the T201A has amuch larger effect on
loss of inhibition, which is recovered with the T201S mutant. The results
seen with the sterically restricted analogues of RIS, NE58025 1R6S and
NE58025 1S6R, also reinforce the importance of the BP side chain nitro-
gen interactions with Thr201. The inhibition of the Tyr204 mutants by
ZOL was of particular interest. The IC50 for the inhibition indicates that
one molecule of ZOL was inhibiting more than one molecule of the mu-
tant FPPS. It is possible that by binding to one member of the dimer
pair, one ZOL molecule prevents both from turning over substrate,
485M.K. Tsoumpra et al. / Bone 81 (2015) 478–486maybe by locking the FPPS into a rigid conformation that prevents its twin
frommoving.
PAM and IBN were not predicted to form any interaction with
Thr201 and this is reﬂected in the lack of change in their inhibition
seen in the mutants of this residue. However ALN was predicted to
form an H-bond with Thr201 but not the carbonyl of Lys200 [17] and
surprisingly there was no change in inhibition with the T201A mutant.
It has been suggested that the PAM nitrogen could H-bond to the OH
of Tyr204 [17] and it is possible that ALN might also make this interac-
tion. However in the Y204Fmutant any expected reduction in inhibition
seems to be masked by an unexpected interaction, possibly due to
movement of the IPP into amore hydrophobic environment, as the inhi-
bition returns to that ofwtFPPSwhen the ring of this residue is removed
and replaced with the methyl in Y204A.
In conclusion, we have identiﬁed novel functions of the human FPPS
active site residues Thr201 and Tyr204 in catalysis as well as substrate
and inhibitor binding. This study provides new insights into the molec-
ular mechanisms of actions of N-BPs by illustrating the involvement of
multiple interactions between the side chain of N-BPs with Thr201
and Tyr204 residues, which contribute to their strength of binding.
Further understanding of bisphosphonate interaction with FPPS aids
in explaining the clinical potency of the bisphosphonates. We hope
that this information would also enable the future development of
bisphosphonates or other speciﬁc FPPS inhibitors for other applications.
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